Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “HEMOSTASIS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,045 records · Page 58Linked to original sources
PubMed1999

Vasoseal hemostasis following coronary interventions with abciximab.

Femoral arteriotomy management using a collagen vascular hemostasis device (VasoSeal, Datascope Corporation, Montvale, New Jersey) was studied in 50 consecutive patients following interventional coronary procedures performed with abciximab (ReoPro, Eli Lilly and Company, Indianapolis, Indiana). Low-dose weight-adjusted or no heparin was employed. The first 25 patients were permitted to sit up after 6 hours with ambulation the following day. The second 25 patients were allowed to sit up after 1 hour and ambulate after 6 hours. Despite early activity and ambulation, there were no hemorrhagic complications including hematoma, pseudoaneurysm, blood transfusion, or surgical repair. Hemoglobin and platelet counts remained stable overnight prior to discharge. This pilot study demonstrates the potential efficacy of VasoSeal in achieving early sheath removal and ambulation in patients undergoing interventional procedures using ReoPro.

Abciximab↗
PubMed1975

The role of vitamins in hemostasis.

The physiological mechanism to prevent and control abnormal bleeding is dependent on three vitamins (C, K, and Q). Two of these are unequivocally established as essential for hemostasis while the existence of the third (Q) is supported by experimental evidence and by clinical and therapeutic observations (Quick 1972; Quick 1974). The interrelationship of these three vitamins has remained moot except for clue observations. Both vitamins C and K have a key structure in their molecules which supplies a redox mechanism, ascorbic acid and 2-methyl, 1,4-naphthoquinone, respectively. Both vitamins are concerned with growth. Lack of vitamin C, which clinically is the basic defect of scurvy, does not appear to cause a defect in blood coagulation while vitamin K affects the clotting mechanism by being essential for the production of four distinct clotting factors: prothrombin, factors VII, IX and X. In this presentation an attempt is made to correlate the action of the vitamin K-dependent clotting factors grouping them in a diagram to show how two systems of thrombin formation exist, one being essentially intrinsic, the second extrinsic requiring tissue thromboplastin and factor VII. The possible interlocking of vitamin Q in this mechanism is presented.

Animals↗
PubMed2001

[Frequency of antiphospholipid antibodies and Leiden mutation of hemostasis Factor V in unexplained recurrent fetal and embryo loss].

Object of the study are women with a history of unexplained recurrent embryo, fetal and early neonatal death, severe preeclampsia, fetal growth retardation, abruptio placentae, puerperal thromboses. Quite often placental insufficiency is linked to abnormal vascular system and hemostatic disturbancies. In about 65% of the women with a complicated and in 18% of the women with a normal pregnancy are observed different genetic anomalies that lead to a hypercoagulative state. A major place is taken by the Leiden mutation of hemostasis factor V, by protein C and protein S deficiency, etc. Another disease that leads to arterial and venous thromboses and is most often linked to recurrent miscarriage is the antiphospholipid syndrome. Many authors confirm the findings of large placental infarctions and thromboses in women who are positive for antophospholipid antibodies.

Abortion, Habitual↗
PubMed2002

[Monoclonal antibody therapy for disorders of hemostasis and coagulation].

Monoclonal antibody therapies have conducted to not only hematologic malignancies but also disorders of hemostasis and coagulation. This article describes the recent advances of monoclonal antibody therapy for bleeding disorders such as idiopathic thrombocytopenic purpura(ITP), hemophilia A, disseminated intravascular coagulation(DIC), and thrombosis. Rituximab, chimeric anti-CD20 monoclonal antibody treatment has a valuable effect in the patients with ITP, and clinical trials using anti-CD40 ligand monoclonal antibody for ITP are underway. Anti-CD40 ligand monoclonal antibody can be an alternative therapy for hemophilia A patients with inhibitors to factor VIII. In thrombosis, anti-tissue factor monoclonal antibody and anti-factor IX(a) monoclonal antibody were established as novel anticoagulant regents. Plasminogen activator inhibitor-1(PAI-1) increases in endotoxin-induced DIC and many thrombotic diseases such as myocardial infarction, type 2 diabetes mellitus, and hyperlipidemia. Anti-PAI-1 monoclonal antibody reduced fibrin deposition in DIC mouse model. Treatment of these monoclonal antibodies for the molecules regulating coagulation-fibrinolysis system may be utilized for acute coronary syndrome and venous thrombosis.

Animals↗
PubMed2003

[Disorders in the immune regulation and hemostasis as factors triggering the proliferative retinopathy in diabetes mellitus].

A comprehensive clinical- immunological- and-hemostasiological study of the lachrymal fluid and blood of 105 patients with diabetic retinopathy (DR) showed that an "extreme" activity of the local antibody-dependent response to collagens, DNA, cytokine, TNF-alpha, increased levels of the circulating immune complexes (CIC) and of antibodies to DNA in the blood serum as well as local immune insufficiency and deficiency of free antibodies to collagens and TNF-alpha in the lachrymal fluid and serum during the onset of proliferative forms and traction retinal detachment are the key manifestations of the immune pathology in a progressing DR. Signs of hypercoagulation, free heparin deficiency, a reduced activity of fibrinolysis and insufficiency of the anti-thrombin system were detected with the development of the chronic syndrome of disseminated intravascular blood coagulation. Trends of the immunohemostatic correction of the activity of the local and systemic autoimmune responses and of hemostasis were substantiated during the generally accepted therapy of diabetes mellitus and of systemic micro- and-macroangiopathy.

Adolescent↗
PubMed2001

State-of-the-art knowledge on thrombosis and hemostasis.

The XVIII Congress of the International Society on Thrombosis and Haemostasis, held July 6-12, 2001, in Paris, France, covered the latest advances in the field of thrombosis and hemostasis, including vascular biology. Plenary conferences, state-of-the-art lectures, symposia, and oral and poster presentations focused most of the attention on the current research on the pathogenesis and treatment of thrombotic and hemorrhagic disorders and provided updates on trials currently under way or already completed.

Journal Article↗
PubMed2003

[Non ST elevation acute coronary syndrome: early use of pravastatin or atorvastatin is associated with divergent changes of parameters of hemostasis].

PURPOSE: To find out whether pravastatin and atorvastatin rapidly (in 1-2 weeks) and similarly affect hemostasis in patients with non-ST elevation acute coronary syndrome (NSTEACS). METHODS: Ninety aspirin and heparin treated patients with NSTEACS were randomized <24 hours from pain onset to open pravastatin 40 mg/day (n=31), atorvastatin 10 mg/day (n=30) or atorvastatin 40 mg/day (n=29). At baseline, on days 7, 14 plasma thrombin-antithrombin complex (TAT), prothrombin fragments 1+2 (F1+2), D-dimer, von Willebrand factor (vWF) were measured by ELISA. Results were compared with data from controls (n=18) of another randomized study on similarly treated patients. RESULTS: In all treatment groups levels of low-density lipoprotein cholesterol (LDLCH) were lowered by days 7 (p<0,01) and 14 (p<0,01 vs. baseline and for both atorvastatin groups vs. day 7). In pravastatin group levels of TAT and F1+2 decreased, while vWF level increased. In atorvastatin groups levels of TAT and F 1+2 increased while level of vWF decreased. Contrary to pravastatin group changes in atorvastatin treated patients more resembled those in controls not receiving lipid lowering drugs. Changes of both LDLCH and TCH directly correlated only with changes of vWF (r=0.23, p=0.03 and r=0.25, p=0.02, respectively). No consistent changes of D-dimer occurred. CONCLUSION: Early use of atorvastatin and pravastatin in patients with NSTEACS was associated with rapid divergent changes of some hemostatic parameters. Except lowering of von Willebrand factor changes in atorvastatin treated patients more resembled those in controls not receiving lipid lowering drugs. Von Willebrand factor was the only parameter which changes weakly but significantly correlated with changes of CH and LDL CH levels.

Acute Disease↗
PubMed1992

Postextraction hemostasis in patients on anticoagulant therapy: the use of a fibrin sealant.

A simple and safe method of achieving hemostasis after tooth extraction in patients on anticoagulant therapy is described. The use of a tissue sealant turns a complicated, difficult, and risky dental procedure into a simple one, suitable for any dental clinic. Sixty-one teeth were extracted in 23 sessions. Only four cases of very slight postsurgical bleeding were reported. Dental treatment of the majority of these medically compromised people can be performed by private practitioners, without referring the patients to specialty care centers.

Adult↗
PubMedDate not supplied

[Changes in hemostasis in the postoperative period].

Hemostasis was investigated in the postoperative stage (at 24 hours and at 5 days) in 20 patients that had underwent major surgical interventions. The test applied for study of blood coagulation included : thrombocyte counting, the test of Howell, the activated recalcification time, the activated partial thromboplastin time, the prothrombin time (Quick), the thrombin time, estimation of fibrinogen concentration, the protamine sulphate test. The activity of the fibrinolytic system was investigated by the euglobulin clot lysis test and by the method of fibrin plates, while fibrinolysis inhibitors were assessed by determination of serum antiplasmines. Also the fibrinolytic degratation products were evaluated. The results indicate a biological condition that can be classified as "thrombophilia", characterized by hyperfibrinogenemia, the presence of fibrin monomers, a decrease of the fibrinolytic activators and an increase in the amount of antiplasmins, as well as a high percentage of fibrinolytic degradation products. Although the patients did not show manifest signs of thrombosis in the postoperative period, the results obtained indicate a tendency to intravascular formation and deposition of fibrin and suggest the necessity to apply prophylactic therapy with anticoagulants in the postoperative period.

Anticoagulants↗
PubMed1992

[A case report of oozing type cardiac rupture following acute myocardial infarction: hemostasis with fibrin glue and oxycellulose].

A 65-year-old man was admitted due to acute anterior myocardial infarction. After admission, he fell into cardiac shock. Echocardiogram showed cardiac tamponade due to cardiac rupture. He was immediately transferred to the operating room. After opening the pericardium, 300 ml of bloody pericardial fluid containing coagula was excluded. Hematoma-like infarcted lesion was found on the surface of the left ventricular apex. Because there was no bleeding point, fibrin glue and oxycellulose was fixed on this lesion for pressure hemostasis without any suture. The postoperative course was uneventful.

Aged↗
PubMed2005

[Associations of hemostasis factors genes with early development of ischemic heart disease and manifestation of myocardial infarction in young age].

AIM: To study polymorphisms of genes of factors of the system of hemostasis in young patients with ischemic heart disease (IHD). MATERIAL: Two groups of patients participated in the study: patients with first manifestation of IHD at the age < or = 50 years (men) or < or = 55 years (women) (n=158), and patients with first IHD manifestation at the age > or = 70 years (n=92). METHODS: We studied polymorphic markers of genes encoding clotting factors V (F5) and VII (F7), subunit IIIa of platelet integrin (ITGB3), beta-chain of fibrinogen (FGB) and tissue plasminogen activator type 1 (PLANH1). RESULTS: After separation of a subgroup of patients with MI without preceding angina we revealed significant differences in distribution of frequencies of genotypes of polymorphic marker C(-426)T of factor V gene: genotype TT was significantly more frequent in young (14.9%) than in old (2%) patients (p=0.008). Multifactorial logistic regression revealed independent association of early IHD with smoking (OR 6.112 [2.567-14.552]; p<0.001) and presence of genotype TT of C(-426)T polymorphic marker of F5 gene (OR=9.410 [1.074-82.459]; p=0.043). CONCLUSION: Thus we obtained data on the presence of independent association between IHD risk and manifestation of MI in young age with genotype TT of polymorphic marker C(-426)T of F5 gene as well as with traditional risk factors of IHD.

Adult↗
PubMed1992

Total hepatic mesh wrap for hemostasis.

To improve hemostasis and avoid the complications of perihepatic packing, a technique of hepatic tamponade using total mesh wrap is reported. The method is geometrically, technically and mechanically feasible and appears to be effective in controlling severe parenchymatous bleeding.

Animals↗
PubMed2005

[Thrombocyte-vascular and sero-coagulation hemostasis, and blood lipids in the acute period of ischemic stroke].

The subjects of the study were 46 patients at the acute stage of a first or repeated ischemic stroke (IS). The study revealed prevalence of procoagulating and thrombocyte activity of hemostasis, pronounced deficiency of physiological anticoagulants, high activity of Willebrand factor, and dislipidemia in these patients. The results show that secondary IS prophylaxy require combined antiaggregant therapy or combined therapy including anticoagulants and antithrombocyte agents plus correction of dislipidemia.

Acute Disease↗
PubMed2006

[Effects of a hemostatic jelly with polylactic acid on hemostasis of injured cancellous bone].

OBJECTIVE: To prepare a self-made compound, hemostatic jelly with polylactic acid (PLA), which has the hemostatic and absorbable effect on injured cancellous bone. METHODS: Two bone defects of 5 mm in diameter and 4 mm in depth were subjected on 20 health rabbits by drilling through their either outside plate of the iliac, and were filled with hemostatic jelly(group A), bone wax(group B) and blank(group C) respectively. Hemostasis were observed and recorded after 1 and 10 minutes. Five specimens were harvested at 2, 4, 8 and 12 weeks postoperatively for histological observation. RESULTS: (1) Hemostatic effect: Bleeding of injured spongy bone stopped within 10 minutes after the treatment of hemostatic jelly and bone wax, but bleeding of blank did not stop. Hemostatic jelly and bone wax adhered to bone defects firmly within 10 minutes was after the treatment. (2) Absorbable effect: Hemostatic jelly and bone defects have not changed visibly in the first 2 weeks. With histological observation 4 to 8 weeks after the operation, hemostatic jelly was absorbed gradually and replaced by osteogeneous tissue. It was absorbed completely after 8 to 12 weeks. Bone wax was not absorbed after 12 weeks, no new bone tissue was observed at bone wax area. The blank was replaced by connective tissue and osteogeneous tissue partially after 12 weeks. CONCLUSION: The compound hemostatic jelly manifests both hemostatic and absorbable effects on injured cancellous bone and may substitute for bone wax in clinical application.

Animals↗
PubMed1991

Recommendations for the evaluation and treatment of neonatal autoimmune and alloimmune thrombocytopenia. The Working Party on Neonatal Immune Thrombocytopenia of the Neonatal Hemostasis Subcommittee of the Scientific and Standardization Committee of the ISTH.

The following recommendations of the Neonatal Hemostasis Subcommittee of the Scientific and Standardization Committee of the ISTH for the management of neonatal immune thrombocytopenia were prepared by the working party on neonatal immune thrombocytopenia. Evaluation, diagnosis, and treatment of the mother and neonate with alloimmune and autoimmune thrombocytopenia are discussed and current recommendations provided. This document is likely to require frequent future revision(s).

Autoimmune Diseases↗
PubMed1991

Glycine as an irrigant during microsurgical hemostasis. A microsurgeon's observations.

The "drip-stop-coagulate" technique used during microsurgery is tedious and, at times, frustrating when electrolyte-rich solutions are used as an irrigant. Glycine, a nonelectrolyte solution, allows the gynecologist to apply electrosurgical energy in a fluid medium; lactated Ringer's solution, the irrigant frequently used by microsurgeons, will not. When, during microsurgery, glycine is used in place of lactated Ringer's solution, the origin of the bleeding site can be easily isolated and coagulated during irrigation, assisting the surgeon in precise and complete hemostasis.

Electrocoagulation↗
PubMed1990

Effect of nitrox saturation diving upon platelet hemostasis.

Two nitrox saturation exposures (seven- and nine-days) at a pressure equivalent to 40 and 45 m (pO2 40-50 kPa) with three divers were carried out. During one exposure 6 excursions from the plateau to the depth of 70 m (one hour) and 60 m (four hours) were made. Before and after the exposures blood platelet count, aggregation and adhesion of blood cells were determined. After the first series of diving a slight increase of adhesion and aggregation was observed, after the other one, despite the larger depth and the excursions from the saturation plateau to 60 and 70 m, a slight decrease of adhesion occurred. This allows to conclude that the phenomenon is related to the decompression load degree as well as to the condition of the divers. Finding about the effect of decompression upon the processes of hemostasis may be useful for the evaluation of the verified system of saturation decompression.

Decompression↗